Kramm, Thorsten
Wilkens, Heinrike
Fuge, Jan
Schäfers, Hans-Joachim
Guth, Stefan
Wiedenroth, Christoph B.
Weingard, Bettina
Huscher, Doerte
Pittrow, David
Cebotari, Serghei
Hoeper, Marius M. http://orcid.org/0000-0001-9086-2293
Mayer, Eckhard
Olsson, Karen M.
Article History
Received: 28 November 2017
Accepted: 8 February 2018
First Online: 15 February 2018
Compliance with ethical standards
:
: T. Kramm has received speaker fees from Actelion, Bayer and GSK. H. Wilkens has received speaker fees and honoraria for consultation from Actelion, Bayer, Boehringer-Ingelheim, GSK, MSD, Pfizer and Roche. J. Fuge has nothing to disclose. HJ Schäfers has received speaker fees from Bayer. S. Guth has received speaker fees from Actelion, Bayer, GSK and Pfizer. CB Wiedenroth has received speaker fees or consultant honoraria from Actelion, Bayer AG, BTG, MSD and Pfizer. B. Weingard has received speaker fees and consultation honoraria from Bayer. D. Huscher has received author and consultation honoraria from Actelion. D. Pittrow has received speaker fees or honoraria for consultations from Actelion, AstraZeneca, Aspen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Shield and Pfizer. M.M. Hoeper has received speaker fees and honoraria for consultations from Actelion, Bayer, Gilead, GSK, MSD and Pfizer. S. Cebotari has nothing to disclose. E. Mayer has received speaker and consulting fees from Actelion, Bayer, GSK, and Pfizer. KM Olsson has received speaker fees and honoraria for consultations from Actelion, Bayer, GSK, Pfizer and United Therapeutics.